Bibliografische Daten

Dokument WO002011161186A1 (Seiten: 56)

Bibliografische Daten Dokument WO002011161186A1 (Seiten: 56)
INID Kriterium Feld Inhalt
54 Titel TI [EN] METHOD FOR IN VITRO DIAGNOSING SEPSIS UTILIZING BIOMARKER COMPOSED OF MORE THAN TWO DIFFERENT TYPES OF ENDOGENOUS BIOMOLECULES
[FR] MTHODE DE DIAGNOSTIC IN VITRO D'UNE SEPSIE EN UTILISANT UN BIOMARQUEUR COMPOS DE PLUS DE DEUX TYPES DIFFRENTS DE BIOMOLCULES ENDOGNES
71/73 Anmelder/Inhaber PA BAUER MICHAEL, DE ; BIOCRATES LIFE SCIENCES AG, AT ; DEIGNER HANS-PETER, DE ; KOHL MATTHIAS, DE
72 Erfinder IN BAUER MICHAEL, DE ; DEIGNER HANS-PETER, DE ; KOHL MATTHIAS, DE
22/96 Anmeldedatum AD 22.06.2011
21 Anmeldenummer AN 2011060495
Anmeldeland AC EP
Veröffentlichungsdatum PUB 29.12.2011
33
31
32
Priorität PRC
PRN
PRD
EP
10167032
20100623
51 IPC-Hauptklasse ICM C12Q 1/68 (2006.01)
51 IPC-Nebenklasse ICS G01N 33/50 (2006.01)
IPC-Zusatzklasse ICA
IPC-Indexklasse ICI
Gemeinsame Patentklassifikation CPC Neues Fenster: Externer Link Gemeinsame Patentklassifikation C12Q 2600/178 C12Q 2600/178
Neues Fenster: Externer Link Gemeinsame Patentklassifikation C12Q 2600/118 C12Q 2600/118
Neues Fenster: Externer Link Gemeinsame Patentklassifikation G01N 33/5308 G01N 33/5308
Neues Fenster: Externer Link Gemeinsame Patentklassifikation G16B 40/00 G16B 40/00
Neues Fenster: Externer Link Gemeinsame Patentklassifikation G16B 40/20 G16B 40/20
Neues Fenster: Externer Link Gemeinsame Patentklassifikation G01N 2800/26 G01N 2800/26
Neues Fenster: Externer Link Gemeinsame Patentklassifikation C12Q 2600/158 C12Q 2600/158
Neues Fenster: Externer Link Gemeinsame Patentklassifikation C12Q 1/6883 C12Q 1/6883
MCD-Hauptklasse MCM C12Q 1/68 (2006.01)
MCD-Nebenklasse MCS G01N 33/50 (2006.01)
MCD-Zusatzklasse MCA
57 Zusammenfassung AB [EN] The present invention relates to an in vitro method for predicting a likelihood of an onset of a sepsis by a) selecting at least two distinct types of biomolecules, wherein said types of biomolecules are selected from the group consisting of: RNAs and/or their DNA counterparts, mRNAs and/or their DNA counterparts, non-coding RNAs and/or their DNA counterparts, microRNAs and/or their DNA counterparts, and endogenous target metabolites; b) measuring at least one parameter selected from the group consisting of presence or absence, qualitative and/or quantitative molecular pattern and/or molecular signature, level, amount, concentration and expression level of a plurality of biomolecules of each species in said sample using said two sets of distinct types of biomolecules and storing the obtained set of values as raw data in a database; after mathematical processing predict a class label of an obtained data set in order to calculate prognostic likelihoods.
[FR] La prsente invention concerne une mthode in vitro de prdiction de la probabilit d'apparition d'une sepsie par a) slection d'au moins deux types distincts de biomolcules, lesdits types de biomolcules tant choisis dans le groupe constitu par : les ARN et/ou leurs quivalents ADN, les ARNm et/ou leurs quivalents ADN, les ARN non codants et/ou leurs quivalents ADN, les microARN et/ou leurs quivalents ADN, et les mtabolites cibles endognes ; b) mesure d'au moins un paramtre choisi dans le groupe constitu par la prsence ou l'absence, la distribution et/ou la signature molculaire qualitative et/ou quantitative, les niveaux, la quantit, la concentration et les niveaux d'expression d'une multitude de biomolcules de chaque espce dans ledit chantillon l'aide de deux ensembles de types distincts de biomolcules, et le stockage de l'ensemble de valeurs obtenues sous forme de donnes brutes dans une base de donnes ; aprs un traitement mathmatique, prdiction d'un marqueur de classe d'un ensemble de donnes obtenues pour calculer les probabilits de pronostic.
Korrekturinformation KORRINF
56 Entgegengehaltene Patentdokumente/Zitate,
in Recherche ermittelt
CT
US020040157242A1
WO002006071583A2
56 Entgegengehaltene Patentdokumente/Zitate,
vom Anmelder genannt
CT EP000009180820A
EP000009167018A
US020080050829A1
WO002008055158A2
56 Entgegengehaltene Nichtpatentliteratur/Zitate,
in Recherche ermittelt
CTNP CATALIN VASILESCU ET AL: "MicroRNA Fingerprints Identify miR-150 as a Plasma Prognostic Marker in Patients with Sepsis", PLOS ONE, vol. 4, no. 10, 1 January 2009 (2009-01-01), pages E7405 - E7405, XP055004043, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0007405 7;
CLAUS R A ET AL: "Approaching clinical reality: markers for monitoring systemic inflammation and sepsis", CURRENT MOLECULAR MEDICINE, BENTHAM SCIENCE PUBLISHERS, NL, vol. 10, no. 2, 1 March 2010 (2010-03-01), pages 227 - 235, XP009136621, ISSN: 1566-5240 7;
DEIGNER H P ET AL: "The molecular sepsis signature", CRITICAL CARE MEDICINE, WILLIAMS AND WILKINGS COMPANY, BALTIMORE, MA, US, vol. 37, no. 3, 1 January 2009 (2009-01-01), pages 1137 - 1138, XP009136690, ISSN: 0090-3493 7;
JIA-FENG WANG ET AL: "Serum miR-146a and miR-223 as potential new biomarkers for sepsis", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 394, no. 1, 26 March 2010 (2010-03-26), pages 184 - 188, XP055004041, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2010.02.145 7;
KOTB M: "Septomics: Application of systems approaches to sepsis - potential for personalized management of septic patients", CURRENT PHARMACOGENOMICS AND PERSONALIZED MEDICINE 2010 BENTHAM SCIENCE PUBLISHERS B.V. NLD, vol. 8, no. 2, 1 June 2010 (2010-06-01) - 1 June 2010 (2010-06-01), pages 97 - 107, XP008140242, ISSN: 1875-6921 7;
MEMIS ET AL: "High C-reactive protein and low cholesterol levels are prognostic markers of survival in severe sepsis", JOURNAL OF CLINICAL ANESTHESIA, BUTTERWORTH PUBLISHERS, STONEHAM, GB, vol. 19, no. 3, 1 May 2007 (2007-05-01), pages 186 - 191, XP022093314, ISSN: 0952-8180, DOI: DOI:10.1016/J.JCLINANE.2006.10.008 7;
MOYER E ET AL: "MULTIPLE SYSTEMS ORGAN FAILURE 6. DEATH PREDICTORS IN THE TRAUMA SEPTIC STATE THE MOST CRITICAL DETERMINANTS", JOURNAL OF TRAUMA, WILLIAMS & WILKINS, US, vol. 21, no. 10, 1 January 1981 (1981-01-01), pages 862 - 869, XP009129143, ISSN: 0022-5282 7;
SUN B ET AL: "Sepsis and septic shock study in pediatric critical care: An overview of recent Chinese literature", JOURNAL OF PEDIATRIC INFECTIOUS DISEASES,, vol. 4, no. 2, 16 March 2009 (2009-03-16), pages 147 - 152, XP009136723, ISSN: 1305-7707, DOI: DOI:10.3233/JPI-2009-0156 7;
XU P B ET AL: "A metabonomic approach to early prognostic evaluation of experimental sepsis", JOURNAL OF INFECTION, ACADEMIC PRESS, LONDON, GB, vol. 56, no. 6, 1 June 2008 (2008-06-01), pages 474 - 481, XP022690620, ISSN: 0163-4453, [retrieved on 20080508], DOI: DOI:10.1016/J.JINF.2008.03.011 7
56 Entgegengehaltene Nichtpatentliteratur/Zitate,
vom Anmelder genannt
CTNP "American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis", CRIT CARE MED, vol. 20, 1992, pages 864 - 74 1;
ADIB-CONQUY, M., CAVAILLON, J.M.: "Stress molecules in sepsis and systemic inflammatory response syndrome", FEBS LETT, vol. 581, 2007, pages 3723 - 33, XP022191500, DOI: doi:10.1016/j.febslet.2007.03.074 1;
ANGUS, D.C., LINDE-ZWIRBLE, W.T., LIDICKER, J., CLERMONT, G., CARCILLO, J., PINSKY, M.R.: "Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care", CRIT CARE MED, vol. 29, 2001, pages 1303 - 10 1;
ANGUS, D.C., PEREIRA, C.A., SILVA, E.: "Epidemiology of severe sepsis around the world", ENDOCR METAB IMMUNE DISORD DRUG TARGETS, vol. 6, 2006, pages 207 - 12 1;
ANNANE D, AEGERTER P, JARS-GUINCESTRE MC, GUIDET B.: "Current epidemiology of septic shock: the CUB-Rea Network", AM. J. RESPIR. CRIT. CARE MED., vol. 168, 2003, pages 165 - 72 1;
BEGER HG, RAU BM: "Severe acute pancreatitis: Clinical course and management World", J. GASTROENTEROL., vol. 13, 2007, pages 5043 - 51 1;
BERNARD GR, VINCENT JL, LATERRE PF ET AL.: "Efficacy and safety of recombinant human activated protein C for severe sepsis", N. ENGL. J. MED., vol. 344, 2001, pages 699 - 709 1;
BERNARD, G.R., VINCENT, J.L., LATERRE, P.F., LAROSA, S.P., DHAINAUT, J.F., LOPEZ-RODRIGUEZ, A., STEINGRUB, J.S., GARBER, G.E., HEL: "Efficacy and safety of recombinant human activated protein C for severe sepsis", N ENGL J MED, vol. 344, 2001, pages 699 - 709, XP009019299, DOI: doi:10.1056/NEJM200103083441001 1;
BONE, R.C., BALK, R.A., CERRA, F.B., DELLINGER, R.P., FEIN, A.M., KNAUS, W.A., SCHEIN, R.M., SIBBALD, W.J.: "Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine", CHEST, vol. 101, 1992, pages 1644 - 55 1;
BOX, G. E. P., COX, D. R.: "An analysis of transformations (with discussion", JOURNAL OF THE ROYAL STATISTICAL SOCIETY B, vol. 26, 1964, pages 211 - 252 1;
BRUN-BUISSON, C.: "The epidemiology of the systemic inflammatory response", INTENSIVE CARE MED, vol. 26, no. 1, 2000, pages 64 - 74 1;
CRIT CARE MED., vol. 20, no. 6, pages 864 - 874 1;
DEIGNER HP, KOHL M., CRIT CARE MED., vol. 37, no. 3, March 2009 (2009-03-01), pages 1137 - 8 1;
DELLINGER, R.P., CARLET, J.M., MASUR, H., GERLACH, H., CALANDRA, T., COHEN, J., GEA-BANACLOCHE, J., KEH, D., MARSHALL, J.C., PARKE: "Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock", CRIT CARE MED, vol. 32, 2004, pages 858 - 73 1;
DELLINGER, R.P., LEVY, M.M., CARLET, J.M., BION, J., PARKER, M.M., JAESCHKE, R., REINHART, K., ANGUS, D.C., BRUN-BUISSON, C., BEAL: "Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008", CRIT CARE MED, vol. 36, 2008, pages 296 - 327 1;
ENGEL, C., BRUNKHORST, F.M., BONE, H.G., BRUNKHORST, R., GERLACH, H., GROND, S., GRUENDLING, M., HUHLE, G., JASCHINSKI, U., JOHN,: "Epidemiology of sepsis in Germany: results from a national prospective multicenter study", INTENSIVE CARE MED, vol. 33, 2007, pages 606 - 18, XP019510862, DOI: doi:10.1007/s00134-006-0517-7 1;
FERREIRA FL, BOTA DP, BROSS A ET AL.: "Serial evaluation of the SOFA score to predict outcome in critically ill patients", JAMA, vol. 286, 2002, pages 1754 - 1758 1;
GARZON R, VOLINIA S, LIU CG, FERNANDEZ-CYMERING C, PALUMBO T, PICHIORRI F, FABBRI M, COOMBES K, ALDER H, NAKAMURA T: "MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia", BLOOD, vol. 111, no. 6, 2008, pages 3183 - 9, XP002553516, DOI: doi:10.1182/blood-2007-07-098749 1;
GRIFFITHS-JONES S, SAINI HK, VAN DONGEN S: "Enright AJ. miRBase: tools for microRNA genomics", NAR, vol. 36, 2008, pages D154 - D158 1;
HUBER W, VON HEYDEBRECK A, SUELTMANN H, POUSTKA A, VINGRON M.: "Variance Stabilization Applied to Microarray Data Calibration and to the Quantification of Differential Expression", BIOINFORMATICS, vol. 18, 2002, pages 96 - 104 1;
L.M. COPE ET AL., BIOINFORMATICS, vol. 20, no. 3, 2004, pages 323 - 331 1;
L.M. COPE, BIOINFORMATICS, vol. 20, no. 3, 2004, pages 323 - 331 1;
LEVI, M.: "Activated protein C in sepsis: a critical review", CURR OPIN HEMATOL, vol. 15, 2008, pages 481 - 6 1;
LEVY M, FINK M, MITCHELL P, MARSHALL JC, ABRAHAM E ET AL., SCCM/ESICM/ACCP/ATS/SIS, 2001 1;
M. A. HALL, G. HOLMES., IEEE TRANSACTIONS ON KNOWLEDGE AND DATA ENGINEERING, vol. 15, no. 6, 2003, pages 1437 - 1447 1;
MARSHALL JC, COOK DJ, CHRISTOU NV ET AL.: "Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome", CRIT CARE MED, vol. 23, 1995, pages 1638 - 1652, XP008062039, DOI: doi:10.1097/00003246-199510000-00007 1;
MARSHALL, J.C., REINHART, K.: "Biomarkers of sepsis", CRIT CARE MED, vol. 37, 2009, pages 2290 - 8, XP009136622 1;
MARSHALL, J.C.: "Biomarkers of sepsis", CURR INFECT DIS REP, vol. 8, 2006, pages 351 - 7 1;
MARTIN, G.S., MANNINO, D.M., EATON, S., MOSS, M.: "The epidemiology of sepsis in the United States from 1979 through 2000", N ENGL J MED, vol. 348, 2003, pages 1546 - 54 1;
MEISNER M, TSCHAIKOWSKY K, HUTZLER A, SCHICK C, SCHUTTLER J.: "Postoperative plasma concentrations of procalcitonin after different types of surgery", INTENSIVE CARE MED, vol. 24, no. 7, 1998, pages 680 - 4, XP019699679 1;
MOYER, E. ET AL.: "Multiple Systems Organ Failure: VI. Death Predictors in the Trauma-Septic State - The Most Critical Determinants", THE JOURNAL OF TRAUMA, vol. 21, 1981, pages 862 - 869, XP009129143 1;
POCHET, N., DE SMET, F., SUYKENS, J.A., DE MOOR, B.L.: "Systematic benchmarking of microarray data classification: assessing the role of non-linearity and dimensionality reduction", BIOINFORMATICS, vol. 20, no. 17, 2004, pages 3185 - 95 1;
R.A. IRIZARRY ET AL., BIOINFORMATICS, vol. 22, no. 7, 2006, pages 789 - 794 1;
R.A. IRIZARRY, BIOINFORMATICS, vol. 22, no. 7, 2006, pages 789 - 794 1;
RAJ CHARI ET AL., BMC BIOINFORMATICS, vol. 9, 2008, pages 422 1;
RAMASWAMY S, TAMAYO P, RIFKIN R, MUKHERJEE S, YEANG CH, ANGELO M, LADD C, REICH M, LATULIPPE E, MESIROV JP: "Multiclass cancer diagnosis using tumor gene expression signatures", PROC NATL ACAD SCI USA., vol. 98, no. 26, 2001, pages 15149 - 54, XP002649367, DOI: doi:10.1073/pnas.211566398 1;
SCHUETZ, P., CHRIST-CRAIN, M., MULLER, B.: "Biomarkers to improve diagnostic and prognostic accuracy in systemic infections", CURR OPIN CRIT CARE, vol. 13, 2007, pages 578 - 85 1;
T. M. MITCHELL: "Machine Learning.", 1997, MC GRAW-HILL 1;
XU, PING-BO ET AL.: "A metabolomic approach to early prognostic evaluation of experimental sepsis", JOURNAL OF INFECTION, vol. 56, 2008, pages 474 - 481, XP022690620, DOI: doi:10.1016/j.jinf.2008.03.011 1
Zitierende Dokumente Dokumente ermitteln
Sequenzprotokoll
Prüfstoff-IPC ICP C12Q 1/68